$4.93
0.061.23%
Pre-Market: 7:42 AM EDT
15 minutes delayed
Comments
Loading...
Monte Rosa Therapeutics
GLUENASDAQ
want to know what
the Bulls & Bears Say?
Monte Rosa Therapeutics (NASDAQ:GLUE) Stock, Analyst Ratings, Price Targets, Forecasts
Monte Rosa Therapeutics Inc has a consensus price target of $17.78 based on the ratings of 9 analysts. The high is $30 issued by Guggenheim on July 19, 2021. The low is $11 issued by Wedbush on May 22, 2024. The 3 most-recent analyst ratings were released by Piper Sandler, Wedbush, and Wedbush on June 28, 2024, May 22, 2024, and February 15, 2024, respectively. With an average price target of $12.67 between Piper Sandler, Wedbush, and Wedbush, there's an implied 156.93% upside for Monte Rosa Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Piper Sandler
Wedbush
JP Morgan
Credit Suisse
Wells Fargo
1calculated from analyst ratings
Analyst Ratings for Monte Rosa Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/28/2024 | Buy Now | 224.54% | Piper Sandler | Edward Tenthoff | $16 → $16 | Reiterates | Overweight → Overweight | Get Alert |
| 05/22/2024 | Buy Now | 123.12% | Wedbush | Robert Driscoll | → $11 | Reiterates | Outperform → Outperform | Get Alert |
| 02/15/2024 | Buy Now | 123.12% | Wedbush | Robert Driscoll | → $11 | Initiates | → Outperform | Get Alert |
| 10/19/2023 | Buy Now | 123.12% | JP Morgan | Eric Joseph | $31 → $11 | Maintains | Overweight | Get Alert |
| 08/11/2023 | Buy Now | 123.12% | Credit Suisse | Richard Law | → $11 | Reiterates | Neutral → Neutral | Get Alert |
| 05/12/2023 | Buy Now | 123.12% | Credit Suisse | Richard Law | → $11 | Reiterates | Neutral → Neutral | Get Alert |
| 03/17/2023 | Buy Now | 123.12% | Credit Suisse | Richard Law | $12 → $11 | Maintains | Neutral | Get Alert |
| 01/03/2023 | Buy Now | 285.4% | Wells Fargo | Derek Archila | → $19 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 10/13/2022 | Buy Now | 346.25% | UBS | Eliana Merle | → $22 | Initiates | → Buy | Get Alert |
| 08/15/2022 | Buy Now | 305.68% | Jefferies | Kelly Shi | → $20 | Initiates | → Buy | Get Alert |
| 05/12/2022 | Buy Now | 325.96% | Piper Sandler | Edward Tenthoff | $40 → $21 | Maintains | Overweight | Get Alert |
| 04/28/2022 | Buy Now | 285.4% | Credit Suisse | Richard Law | → $19 | Initiates | → Neutral | Get Alert |
| 02/10/2022 | Buy Now | 285.4% | Wells Fargo | Derek Archila | → $19 | Initiates | → Equal-Weight | Get Alert |
| 10/14/2021 | Buy Now | 305.68% | SVB Leerink | Andrew Berens | — | Initiates | → Market Perform | Get Alert |
| 07/19/2021 | Buy Now | 508.52% | Guggenheim | — | — | Initiates | → Buy | Get Alert |
| 07/19/2021 | Buy Now | 711.36% | Piper Sandler | Edward Tenthoff | — | Initiates | → Overweight | Get Alert |
| 07/19/2021 | Buy Now | 670.79% | JP Morgan | Eric Joseph | — | Initiates | → Overweight | Get Alert |
FAQ
What is the target price for Monte Rosa Therapeutics (GLUE) stock?
The latest price target for Monte Rosa Therapeutics (NASDAQ:GLUE) was reported by Piper Sandler on June 28, 2024. The analyst firm set a price target for $16.00 expecting GLUE to rise to within 12 months (a possible 224.54% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Monte Rosa Therapeutics (GLUE)?
The latest analyst rating for Monte Rosa Therapeutics (NASDAQ:GLUE) was provided by Piper Sandler, and Monte Rosa Therapeutics reiterated their overweight rating.
When was the last upgrade for Monte Rosa Therapeutics (GLUE)?
The last upgrade for Monte Rosa Therapeutics Inc happened on January 3, 2023 when Wells Fargo raised their price target to $19. Wells Fargo previously had an equal-weight for Monte Rosa Therapeutics Inc.
When was the last downgrade for Monte Rosa Therapeutics (GLUE)?
There is no last downgrade for Monte Rosa Therapeutics.
When is the next analyst rating going to be posted or updated for Monte Rosa Therapeutics (GLUE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Monte Rosa Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Monte Rosa Therapeutics was filed on June 28, 2024 so you should expect the next rating to be made available sometime around June 28, 2025.
Is the Analyst Rating Monte Rosa Therapeutics (GLUE) correct?
While ratings are subjective and will change, the latest Monte Rosa Therapeutics (GLUE) rating was a reiterated with a price target of $16.00 to $16.00. The current price Monte Rosa Therapeutics (GLUE) is trading at is $4.93, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.